Meda buys Acton for $135M+, snags asthma inhaler

Swedish pharmaceutical company Meda bought Massachusetts-based Acton Pharmaceuticals, the maker of a new asthma drug-device combo, for more than $135 million plus milestone payments. The inhaler, Aerospan, which delivers the corticosteroid flunisolide, is the only FDA-approved inhaler in its class to incorporate a built-in spacer device, which helps control the delivery of the drug to the lung, according to the company. On top of the agreed-upon upfront payment, Meda offered milestone payments of more than $10 million. Release